(Q44868611)

7 December 2017

title

Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia (English)

1 reference

7 December 2017

1 reference

7

1 reference

7 December 2017

A Amoruso

4

0 references

author name string

V De Francesco

1

1 reference

7 December 2017

N Della Valle

2

1 reference

7 December 2017

V Stoppino

3

1 reference

7 December 2017

N Muscatiello

5

1 reference

7 December 2017

C Panella

6

1 reference

7 December 2017

language of work or name

English

0 references

publication date

1 May 2004

1 reference

Alimentary Pharmacology & Therapeutics

7 December 2017

published in

1 reference

7 December 2017

volume

19

1 reference

7 December 2017

issue

9

1 reference

7 December 2017

page(s)

993-998

1 reference

Relationship between antral lymphocyte density and basal gastrin levels in patients with Helicobacter pylori infection.

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01877.X

Helicobacter pylori infection and the development of gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01877.X

Helicobacter pylori: diseases, tests and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01877.X

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01877.X

A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01877.X

Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01877.X

Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01877.X

A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01877.X

A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01877.X

One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01877.X

Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01877.X

Does Helicobacter pylori eradication affect symptoms in nonulcer dyspepsia: a 5-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01877.X

Two new treatment regimens for Helicobacter pylori eradication: a randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01877.X

Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01877.X

Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01877.X

Factors associated with treatment failure of Helicobacter pylori infection in a developing country

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01877.X

Helicobacter pylori strains and histologically-related lesions affect the outcome of triple eradication therapy: a study from southern Italy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01877.X

cagA Status and eradication treatment outcome of anti-Helicobacter pylori triple therapies in patients with nonulcer dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01877.X

Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01877.X

Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01877.X

A new highly effective short-term therapy schedule for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01877.X

10.1111/J.1365-2036.2004.01877.X

21 January 2018

Identifiers

DOI

1 reference

7 December 2017

1 reference